CVE:KNE

Kane Biotech Competitors

C$0.16

-0.01 (-5.88 %)

(As of 04/12/2021 03:51 PM ET)

Add

Compare

Today's Range

C$0.16

Now: C$0.16▼

C$0.17

50-Day Range

C$0.12

MA: C$0.15▼

C$0.18

52-Week Range

C$0.11

Now: C$0.16▼

C$0.21

Volume90,000 shs

Average Volume111,835 shs

Market CapitalizationC$17.38 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Kane Biotech (CVE:KNE) Vs. COV, EMH, IGX, QPT, CZO, and CTX

Should you be buying KNE stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Kane Biotech, including Covalon Technologies (COV), Emerald Health Therapeutics (EMH), IntelGenx Technologies (IGX), Quest PharmaTech (QPT), Ceapro (CZO), and Crescita Therapeutics (CTX).

Kane Biotech vs. Covalon Technologies Stock

Kane Biotech (CVE:KNE) and Covalon Technologies (CVE:COV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Profitability

This table compares Kane Biotech and Covalon Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kane Biotech	N/A	N/A	N/A
Covalon Technologies	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Kane Biotech and Covalon Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kane Biotech	0	0	0	0	N/A
Covalon Technologies	0	0	0	0	N/A

Valuation & Earnings

This table compares Kane Biotech and Covalon Technologies' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kane Biotech	C$1.34 million	12.95	C$-3,801,490.00	C($0.04)	-4.57
Covalon Technologies	C$23.84 million	1.53	C$-6,144,922.00	C($0.24)	-5.92

Kane Biotech has higher earnings, but lower revenue than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Kane Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Kane Biotech beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.

Kane Biotech vs. Emerald Health Therapeutics Stock

Emerald Health Therapeutics (CVE:EMH) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Emerald Health Therapeutics and Kane Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emerald Health Therapeutics	0	0	0	0	N/A
Kane Biotech	0	0	0	0	N/A

Profitability

This table compares Emerald Health Therapeutics and Kane Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Emerald Health Therapeutics	N/A	N/A	N/A
Kane Biotech	N/A	N/A	N/A

Valuation and Earnings

This table compares Emerald Health Therapeutics and Kane Biotech's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emerald Health Therapeutics	C$13.02 million	4.17	C$-142,699,488.00	C($0.70)	-0.38
Kane Biotech	C$1.34 million	12.95	C$-3,801,490.00	C($0.04)	-4.57

Kane Biotech has lower revenue, but higher earnings than Emerald Health Therapeutics. Kane Biotech is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Kane Biotech beats Emerald Health Therapeutics on 3 of the 5 factors compared between the two stocks.

Kane Biotech vs. IntelGenx Technologies Stock

IntelGenx Technologies (CVE:IGX) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Analyst Recommendations

This is a breakdown of current recommendations for IntelGenx Technologies and Kane Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IntelGenx Technologies	0	0	0	0	N/A
Kane Biotech	0	0	0	0	N/A

Valuation and Earnings

This table compares IntelGenx Technologies and Kane Biotech's top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IntelGenx Technologies	C$1.54 million	47.84	C$-7,274,150.00	C($0.07)	-10.15
Kane Biotech	C$1.34 million	12.95	C$-3,801,490.00	C($0.04)	-4.57

Kane Biotech has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Kane Biotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IntelGenx Technologies and Kane Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IntelGenx Technologies	N/A	N/A	N/A
Kane Biotech	N/A	N/A	N/A

Summary

Kane Biotech beats IntelGenx Technologies on 3 of the 5 factors compared between the two stocks.

Kane Biotech vs. Quest PharmaTech Stock

Quest PharmaTech (CVE:QPT) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Profitability

This table compares Quest PharmaTech and Kane Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quest PharmaTech	N/A	N/A	N/A
Kane Biotech	N/A	N/A	N/A

Valuation and Earnings

This table compares Quest PharmaTech and Kane Biotech's top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest PharmaTech	C$38,871.00	474.71	C$109.88 million	C$0.66	0.17
Kane Biotech	C$1.34 million	12.95	C$-3,801,490.00	C($0.04)	-4.57

Quest PharmaTech has higher earnings, but lower revenue than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Quest PharmaTech and Kane Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest PharmaTech	0	0	0	0	N/A
Kane Biotech	0	0	0	0	N/A

Summary

Quest PharmaTech beats Kane Biotech on 4 of the 5 factors compared between the two stocks.

Kane Biotech vs. Ceapro Stock

Ceapro (CVE:CZO) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ceapro and Kane Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ceapro	0	0	0	0	N/A
Kane Biotech	0	0	0	0	N/A

Valuation & Earnings

This table compares Ceapro and Kane Biotech's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ceapro	C$16.14 million	3.80	C$2.56 million	C$0.03	23.94
Kane Biotech	C$1.34 million	12.95	C$-3,801,490.00	C($0.04)	-4.57

Ceapro has higher revenue and earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ceapro and Kane Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ceapro	N/A	N/A	N/A
Kane Biotech	N/A	N/A	N/A

Summary

Ceapro beats Kane Biotech on 4 of the 5 factors compared between the two stocks.

Kane Biotech vs. Crescita Therapeutics Stock

Crescita Therapeutics (TSE:CTX) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Crescita Therapeutics and Kane Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescita Therapeutics	0	0	0	0	N/A
Kane Biotech	0	0	0	0	N/A

Profitability

This table compares Crescita Therapeutics and Kane Biotech's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Crescita Therapeutics	N/A	N/A	N/A
Kane Biotech	N/A	N/A	N/A

Valuation and Earnings

This table compares Crescita Therapeutics and Kane Biotech's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescita Therapeutics	C$15.64 million	1.12	C$41,296.00	C$0.00	425.00
Kane Biotech	C$1.34 million	12.95	C$-3,801,490.00	C($0.04)	-4.57

Crescita Therapeutics has higher revenue and earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Crescita Therapeutics beats Kane Biotech on 4 of the 5 factors compared between the two stocks.